
Anebulo Pharmaceuticals, Inc. Common Stock
ANEB
ANEB: Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company. It is developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.
moreShow ANEB Financials
Recent trades of ANEB by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by ANEB's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Formulations and methods for treating acute cannabinoid overdose Oct. 12, 2021
Federal grants, loans, and purchases
Followers on ANEB's company Twitter account
Number of mentions of ANEB in WallStreetBets Daily Discussion
Recent insights relating to ANEB
Recent picks made for ANEB stock on CNBC
ETFs with the largest estimated holdings in ANEB
Flights by private jets registered to ANEB